Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 11, Pages 1756
Publisher
MDPI AG
Online
2019-11-09
DOI
10.3390/cancers11111756
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma
- (2019) Iris Helfrich et al. Cancers
- PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
- (2019) Samaresh Sau et al. Cancers
- KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
- (2019) Helen Adderley et al. EBioMedicine
- Comparative analysis of CEACAM1 expression in thin melanomas with and without regression
- (2019) Luciana Nichita et al. Oncology Letters
- PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
- (2019) Yanhui Chen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Rational design of anti-GITR-based combination immunotherapy
- (2019) Roberta Zappasodi et al. NATURE MEDICINE
- Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes
- (2019) Young et al. Cancers
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- (2019) Anand Rotte JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma
- (2019) Wei-Ge Wang et al. LABORATORY INVESTIGATION
- Adaptation and memory in immune responses
- (2019) Gioacchino Natoli et al. NATURE IMMUNOLOGY
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
- (2019) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer
- (2019) Chongkai Wang et al. Molecular Therapy-Oncolytics
- On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment
- (2019) Grazia R. Tundo et al. CHEMOTHERAPY
- Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review
- (2019) Vignesh Ravi et al. Dermatologic Therapy
- Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
- (2019) Mark P. Labrecque et al. JOURNAL OF CLINICAL INVESTIGATION
- Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms
- (2019) Samantha N. Champion et al. MODERN PATHOLOGY
- PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
- (2019) Henning Zelba et al. Cancer Immunology Research
- The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
- (2019) Antje Tunger et al. Journal of Clinical Medicine
- Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
- (2019) Malgorzata Bobrowicz et al. Cancers
- Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors
- (2019) Alberto Vogrig et al. Neurology-Neuroimmunology & Neuroinflammation
- Application of Genome Editing Techniques in Immunology
- (2018) Agata O. Zych et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy
- (2018) Florent Amatore et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model
- (2018) Avner Friedman et al. PLoS One
- Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer
- (2018) John K. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Eradication of spontaneous malignancy by local immunotherapy
- (2018) Idit Sagiv-Barfi et al. Science Translational Medicine
- Next generation immune-checkpoints for cancer therapy
- (2018) Chiara Donini et al. Journal of Thoracic Disease
- TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
- (2018) Alice L. Hung et al. OncoImmunology
- Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
- (2018) John E. Mullinax et al. Frontiers in Oncology
- TIGIT: a novel immunotherapy target moving from bench to bedside
- (2018) Benjamin L. Solomon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
- (2018) Estefanía Paula Juliá et al. Frontiers in Immunology
- Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
- (2018) Ben Tran et al. Journal for ImmunoTherapy of Cancer
- VISTA expressed in tumour cells regulates T cell function
- (2018) Kumuluzi Mulati et al. BRITISH JOURNAL OF CANCER
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
- (2018) Chien-Chun Steven Pai et al. JOURNAL OF CLINICAL INVESTIGATION
- Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors
- (2018) Romualdo Barroso-Sousa et al. Current Oncology Reports
- Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
- (2018) S. Michael Chin et al. Nature Communications
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- Immunoregulatory functions of VISTA
- (2017) Elizabeth C. Nowak et al. IMMUNOLOGICAL REVIEWS
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer
- (2017) Jian-Feng Liu et al. Molecular Oncology
- Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
- (2017) Christian Kellner et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
- (2017) Nicholas A. Manieri et al. TRENDS IN IMMUNOLOGY
- CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice
- (2017) Lucas A. Horn et al. Oncotarget
- Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas
- (2017) Jinhu Li et al. MEDICAL SCIENCE MONITOR
- Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy
- (2017) Catherine A. Sabatos-Peyton et al. OncoImmunology
- Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
- (2017) Inna Serganova et al. Molecular Therapy-Oncolytics
- The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study
- (2017) Alexandra W. Elias et al. Frontiers in Oncology
- Reversing T-cell Dysfunction and Exhaustion in Cancer
- (2016) H. M. Zarour CLINICAL CANCER RESEARCH
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer
- (2016) Seiichi Ikeda et al. Journal of Thoracic Oncology
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
- (2016) Paola Savoia et al. Human Vaccines & Immunotherapeutics
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
- (2015) A. Yonezawa et al. CLINICAL CANCER RESEARCH
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
- (2015) Wenfeng Fang et al. Oncotarget
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- (2014) M. Atefi et al. CLINICAL CANCER RESEARCH
- Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
- (2014) Sabrina Ceeraz et al. ARTHRITIS RESEARCH & THERAPY
- Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review
- (2014) Daniel M Geynisman et al. Human Vaccines & Immunotherapeutics
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
- (2013) Kaori Sakuishi et al. OncoImmunology
- ICOS Mediates the Generation and Function of CD4+CD25+Foxp3+ Regulatory T Cells Conveying Respiratory Tolerance
- (2012) M. Busse et al. JOURNAL OF IMMUNOLOGY
- Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
- (2012) Rona Ortenberg et al. MOLECULAR CANCER THERAPEUTICS
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Inflammatory cytokines as a third signal for T cell activation
- (2010) Julie M Curtsinger et al. CURRENT OPINION IN IMMUNOLOGY
- Safety of biologics, lessons learnt from TGN1412
- (2009) Richard Stebbings et al. CURRENT OPINION IN BIOTECHNOLOGY
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started